MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
17.61
+0.07
+0.40%
After Hours: 17.61 0 0.00% 16:40 05/08 EDT
OPEN
17.48
PREV CLOSE
17.54
HIGH
17.88
LOW
17.32
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
25.00
52 WEEK LOW
8.06
MARKET CAP
2.91B
P/E (TTM)
-5.0691
1D
5D
1M
3M
1Y
5Y
1D
A Look At Dyne Therapeutics (DYN) Valuation After New CNS Tauopathy Data And Pipeline Expansion Potential
Simply Wall St · 1d ago
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 1d ago
Dyne Therapeutics director Jason P. Rhodes disposes of common shares worth $1.94 million
PUBT · 3d ago
Weekly Report: what happened at DYN last week (0427-0501)?
Weekly Report · 6d ago
A Look At Dyne Therapeutics (DYN) Valuation After New MAPT Blood Brain Barrier Data
Simply Wall St · 05/01 19:53
Dyne Therapeutics director Jason P. Rhodes disposes of shares worth $4.18 million
PUBT · 04/30 22:02
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise?
Simply Wall St · 04/30 03:14
Dyne Therapeutics Director Jason P. Rhodes disposes of $6.76 million in shares
PUBT · 04/27 22:16
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Webull offers Dyne Therapeutics, Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.